ADCC Genomic Medicine Approach to MCI and Dementia

ADCC 基因组医学方法治疗 MCI 和痴呆症

• 批准号: 7267702
• 负责人: KATHLEEN Anne WELSH-BOHMER
• 金额: $ 173.97万
• 依托单位: DUKE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-08-01 至 2011-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7267702
• 关键词: ADCC; Genomic; Medicine; Approach; MCI

DESCRIPTION (provided by applicant): This is a new ADCC submission for the Joseph and Kathleen Bryan Alzheimer's Disease Research Center (Bryan ADRC) at Duke University Medical Center. The Bryan ADRC is a multidisciplinary research center established in 1985 which supports and conducts basic science and clinical research in Alzheimer's disease (AD) and related disorders with an emphasis on genetic predisposition, early diagnosis, autopsy confirmation, and educational outreach. Efforts include special focus on the inclusion of minority populations, specifically African-Americans and an emphasis on methodological synergy between our clinic-based and population-based studies. Overall specific aims are to: (1) provide expertise for the diagnosis, prevention, and treatment of mild cognitive disorders and their transition to dementia; (2) provide the structure and context for the ascertainment, evaluation, longitudinal follow-up and research participation of large MCI and AD patient samples and multiplex genetic families; (3) disseminate tissue and provide needed resources for research; (4) facilitate clinical and basic science research of AD and related disorders, leading to advances in the biology of AD with a particular emphasis on genomic approaches (genetics, translational studies, proteomics, metabolomics, etc). The Center's structure consists of four Cores along with a privately supported Genomics Core facilitated by new collaborations with the Institute of Genomic Sciences and Policy at Duke (IGSP) and Glaxo Smith Kline. The Cores include: Clinical; Data Management & Statistics; Neuropathology; and Education; along with two pilot projects per year (determined yearly). The Center integrates, coordinates, and fosters interdisciplinary collaborations at Duke and beyond. The Bryan ADRC provides important resources, e.g., well-characterized patients and control subjects, family information, tissue and biological specimens for the new genomic medicine initiatives. The public health significance brought to bear by the Bryan ADRC with its tremendous new links to technological resources in industry is an efficient, productive, and fully collaborative structure leading to the discovery of the cause(s) of AD and related illnesses with an ultimate goal of developing scientifically well-informed, rational, and effective approaches to the prevention, care, and treatment of memory disorders and overall improvement of health care delivery.

描述（由申请人提供）：这是杜克大学医学中心的约瑟夫和凯瑟琳·布莱恩·阿尔茨海默氏病研究中心（Bryan ADRC）的新的ADCC提交。 Bryan ADRC是一个跨学科研究中心，成立于1985年，该研究中心支持和进行阿尔茨海默氏病（AD）的基础科学和临床研究以及相关疾病，重点是遗传倾向，早期诊断，尸检确认，尸检和教育外展。努力包括特别关注少数族裔人口，特别是非裔美国人，并强调基于诊所和基于人群的研究之间的方法学协同作用。总体具体目的是：（1）为轻度认知障碍的诊断，预防和治疗提供专业知识，及其向痴呆症的过渡； （2）提供了大型MCI和AD患者样本以及多重遗传家族的确定，评估，纵向随访和研究参与的结构和背景； （3）传播组织并提供所需的研究资源； （4）促进了AD和相关疾病的临床和基础科学研究，从而导致AD生物学的进步，特别着重于基因组方法（遗传学，转化研究，蛋白质组学，代谢组学等）。该中心的结构由四个核心组成，以及与杜克（IGSP）基因组科学与政策研究所和葛兰素·史密斯·克莱恩（Glaxo Smith Kline）合作的私人支持的基因组学核心。核心包括：临床； 数据管理和统计； 神经病理学；和教育；以及每年两个试点项目（每年确定）。该中心集成了杜克及以后的跨学科合作，融合，坐标和培养。 Bryan ADRC提供了重要的资源，例如新型基因组医学计划的特征良好的患者和对照组，家庭信息，组织和生物学标本。 Bryan ADRC带来的公共健康意义与行业技术资源的巨大新联系是一种高效，富有成效和完全的协作结构，导致发现AD及相关疾病的原因，最终的目标是发展科学，理性，理性，合理的方法，以及对预防，护理，保健和整体护理的有效方法。